...Good morning. [Foreign language] Okay, then we switch to English. I, I thought I could be lazy in talking in German, but it's a pleasure to do it in English as well, as long as I don't have to talk in French or Spanish or Hungarian, that's super. Very much welcome to Eckert & Ziegler, and I know that some of you are joining also the one-on-ones later on. So what I will try to do in the next 25 minutes, to give you an overview about our company strategy, outlook, performances, and some key financial numbers I'd like to present to you.
Then later on, we will have time for questions, and I know that everybody has to leave thereafter, but I'm more than happy to take your questions with me and then give you answers later on, or you approach us directly. So Eckert & Ziegler, and here, as we are a listed company, you know about the disclaimer. Basically, what we are doing is very simple. We are producing and selling, and producing and selling again. We are doing that because we have a lot of recurring business. It comes again and again and again. So it's a consumable business, but later on you will see that some of these consumables are lasting for longer. But the good part of it is that we know our customers. We know whom we are selling to.
We know a long-lasting relationship, the services and products we are selling, and we are doing this for 30 years. We are doing this 50% in the area of Industry Products and 50% in the area of Pharma. In both areas, there's a lot of recurring, as I mentioned, consumable business, and I would like to start to give you an overview about the first part, that is the Industry sector. In Industry, we are producing radioactive material, isotopes, which are used in a vast majority of all products in industry areas in which you use isotope for industry purposes. That is nutrition, that is nuclear power contamination topics, that is security issue validation. In all these areas, you have what you see here on the left side, small metal sources, radioactive-based, and they are used, for instance, to find new oil sources.
So if the Americans are saying, "Build, baby, drill," then they are using soil and radioactive sources to explore new sources for oil exploration or we have for the nutrition, to make sure that all bananas who are coming from South America are free of any insecticides or any poison or any things you don't want to eat. There are security contamination examinations, and this is done with isotope from Eckert & Ziegler. So there's a lot of areas, approximately 10 different business units in which we are selling these sources, and that is a recurring business, EUR 150 million on a yearly basis, with constant cash flow, which we are producing and selling all over the world. One of those products which we are producing, you see on the right part, this is a small generator, which is... should be seen here. It does not work.
That is— Let me see. Anyway, go back here, and now here. This one here, this is a small generator, like a coffee machine, and you will see the same picture again when I'm talking about a gallium generator. This is a technetium generator for the detection of diseases, non-oncology diseases, other diseases, and that is a big market, and this technetium generator is produced in Argentina, and we are selling this technetium generator not only in Argentina, but, but more and more in South American countries, and later on, also in other countries around the world. The Medical segment represents another 50% of our business, and here again, you see our most important product. And here... It doesn't work.
Anyway, you see again a generator, a gallium generator, and that is our most important product, representing more than 50% of our Medical revenue, because everybody who uses in hospitals, in pharma, in clinics, that generator is looking to find metastasis of cancer, prostate cancer, lung cancer, and other areas. Whenever you are looking in Radiopharmaceutical businesses, you have to use a generator, and this is a gallium generator produced by Eckert & Ziegler. We are market leader with this generator, and this lasts for a year, and it's replaced then by a new generator, and after another year, another generator is coming. So we know here our customers, and we are producing several hundred generators on a yearly basis, selling them to all countries around the world, and that represents our most important product for the last years and also for the years to come.
That all is part of a very dominating development in the radiopharmaceutical world. What is radiopharmaceuticals? What is radioligand therapy? You see it here on the picture. That is the key, what you see. The key is a peptide developed by pharma, and then it has, on the back of that key, it has a radioisotope. That radioisotope is produced by Eckert & Ziegler, it's called gallium, it's called lutetium, it's called actinium, it's called yttrium. Various isotopes, which we are producing, selling to pharma, and they are then combining their peptide, their molecule, which finds its way to the cancer cell, which you see. This is the cancer cell in the upper left corner.
and then it's based and linked together with a radioisotope, and the moment the peptide, the molecule of pharma, has find its way to the cancer, it knocks at the cancer cell, and then the radioisotope starts to beam as a radioactive substance. It has activity, and with the activity, it either eliminates the cancer, so then you can see the cancer, or it has a stronger activity, and then it burns the activity through the cancer cell and destroys the cancer. That is the concept of radioligand therapy, and Eckert & Ziegler is producing these radioisotopes in Berlin, in Germany, but also in North America and South America, and we are also setting up a factory in China. Here you see all the big pharma companies, and the big pharma companies, they are all buying smaller companies in order to develop radiopharmaceuticals.
That is a very important development because for those who are investing in big pharma, you will see that big pharma is purchasing all the smaller ones and paying a lot of money, and most of them are already our customers. What you see here is our projection for the future. We see a strong development of radiopharmaceuticals in the years to come. This is a projection until 2030, so for the next five years, and a lot of new products will entering the market, will produce radiopharmaceuticals in order to make sure that they have a new therapy and a new diagnostic model in order to find cancer, to detect cancer, to show cancer in a X-ray machine or in a PET/CT machine, and then later on, destroy the cancer by a strong activity isotope also produced.
You see here in blue, these are new radiopharmaceuticals, radiotherapeutics, and there is strong uptake in the years to come, and we want to participate in this development. Some of those you see here. Here you see some of our customers in the various isotopes I was just mentioning. You remember that I saw gallium, that is a Ge-generator, the small coffee machine I was presenting to you, but you see also lutetium, Y-90, yttrium, actinium, and others. T hese customers are then approaching us and saying, "Eckert & Ziegler, can you please produce an isotope which we might use and will use for our clinical research, for our clinical development, and later on, then also for the production of radiopharmaceuticals?" Once these clinical studies have performed successfully and they are starting to do commercial development and sales.
Looking to the most advanced isotopes, there I want to point out two of them. One is called lutetium, and the other is called actinium. What you see here is the number of clinical studies currently on its way, almost 200 studies with lutetium and 29 with actinium. All these might come to a successful end. That would be probably too optimistic. Some of these studies will fail, but even if 50% of these studies will be finalized or accomplished successfully, they should become our customers in purchasing lutetium later on. What you see here are some of the potential studies being successful, and then later on, producing radiotherapeutics based on our technique.
In 2026, 2027, and 2028, there are different companies in Germany, in Europe, in China, in Australia, in North America, launching products later on here with lutetium, and this is another one with actinium. These are new isotopes, and they are very promising because the advantage of radioligand therapy is that you only destroy the cancer cell, and all the surrounding tumor is kept untouched. So you can make sure that you only have a specialized and dedicated cancer therapy, which is the most precise technology which is currently available. Now, this is the concept in which we are active, and then you see here for the most two important radioisotopes, you see here some of our customers, big companies, smaller companies. But with all these companies, we are working together, and we are offering them our products, and later on, we also want to make services for them.
That's why we are also offering contract manufacturing work for companies who are saying, "Here is my molecule, my peptide, and here is Eckert & Ziegler's radioisotopes. Can you please bring them together in order to have the ready-made drug available for clinical studies?" This is called CDMO, and once the study has been performed successfully, then it will move into CMO activities. And what you see here are some of our customers who are making use of our services and of our facility in Germany, in North America, and we are also setting up something in China. So what Eckert & Ziegler is offering is both the radioisotope on the one side, the service on the other side.
We do this radioisotope development either in small single-patient doses in a vial, that is for lutetium and for actinium, or as I mentioned earlier, the generator, which lasts for a year and is then replaced. Some highlights of the last quarter, the biggest product, the GalliaPharm, the gallium generator, has now been approved for Japan. An important milestone for us because Japan is a high-priced country, equally priced as North America, and we are very happy to do this together with Novartis. They are launching their product in China, in Japan, and we are doing that together with Novartis, launching our generator. We will do the same in China. We are waiting for approval in China any day from today onwards, again, together with Novartis.
Berenberg, one of today's hosts here at the conference, has taken up coverage last quarter, so whatever you want to know about Eckert & Ziegler, you will find in the Berenberg study. And then we are doing more customers here and there. We are investing into brick-and-mortar. I just want to make here sure that you see some picture. That is Berlin, where we are setting up a new facility for producing more generators. This is a picture of China, where we are setting up together with our joint venture partner, a new factory for the production of radioisotopes, because for us, it is important to be active in China, and the most successful way to be active in China is to produce in China for the Chinese market, and we do this together with a Chinese partner.
So producing in China with a Chinese partner in China, that is what we are aiming for, and that's why we are setting up this factory here in Jintan. That is two hours away from Shanghai, and that will be operative from 2027 onwards. The picture, what you see here is not a AI picture, it's a real picture, so this is how it looks as of today. Now let's spend some minutes about the financial data. I started my presentation in making sure that you see a picture that 50% of our revenue is generated by the Industry segment, the IP. That is the green color, and the red one is the Medical, the Pharma part.
Last year's figures demonstrate a 50/50% share of both segments, whereas the EBIT adjusted is slightly higher in the pharma, and that is important because pharma is the engine of the company and has a stronger profitability margin than the isotope, the Industry part. Nine months data. You see here on the left side, net sales, you see EBIT adjusted, and for those who are more old-fashioned, we are also publishing net income data. We have a challenging first half year. Some of you following our news flow know that we were suffering by a cyberattack. Everybody is talking about AI, we are talking about cyberattacks, and that was harming our Q1 slightly, but now we are recovering. You see sales are higher by 4%, and income and EBIT adjusted is even higher by 8%.
There were some headwinds because of currency, so if you look currency adjusted, the growth would be stronger. Let's look a little bit closer to the numbers, and what you see here is the financial performance about our engine, the Medical business. In the Medical, you see that we were growing double digit by 15%, and the result is even stronger, almost 30% EBIT adjusted, because our generator is growing in three dimensions. We have more customers, we are identifying new markets, and most importantly, the radioligand therapy is not only using as a late-stage treatment by now, but it's coming in as an earlier treatment.
So if someone is suffering by prostate cancer, radiotherapeutics were used only as a late-stage treatment, but the efficacy is so dominant that now you use already radioligand therapy similar to chemotherapy or similar to hormone therapy and surgery in others. So the development is very strong, and that's why we also see an increasing demand of our generators, in particular in North America, and that will also be the growth driver for the years to come and make sure that also the profits will continue to grow in the next year. Isotope, I mentioned, had had a slightly softer start, but now we are recovering, so at the end, we will achieve our plans. Let's have a look to the regional split. 50% basically is generated in Americas, 50% is in Europe, 20% is rest of world, so that's 120%.
So you see that it's a very rough calculation. It's a little bit different. You see here the exact numbers, but we have a fairly good split between Europe and North and South America. But China is growing. You see that if you look backwards, then the Asian number would be single digit. Now it's double digit already, and that is mainly due to the growth in China, and we are working to make that a steady growth in the years to come. And that is important that we have three dimension, not only because of the discussion, because of tariffs, but also geopolitical topics are a very dominant criteria to have different sites where we are producing our radioisotopes. Within Medical, radiopharmaceuticals is the most dominant one.
These are the radioisotopes which we are producing, and here you see the development of the last years, and also what we do expect for the year 2025. There is no guidance yet available for the next year, but here we are. F inally, some KPIs. So our EBIT adjusted is growing by 8%. If you look to ROCE, as 18% is also satisfying. We have cash of EUR 120 million, debt about EUR 15 million, so that has been reduced. We have an equity ratio of more than 50%, and by now more than 2,000 employees, which are in Berlin, in Braunschweig, in Dresden. These are our German sites, but then also in East Coast, in West Coast, in America, in Brazil, China, Buenos Aires, and hopefully more countries to happen. Last slide is the guidance for this year.
We published a number of EUR 320 million. It's hidden by the sign here. EUR 320 million revenue, and around EUR 78 million in terms of EBIT adjusted, and we are confident to be in a corridor of these numbers being achieved by the end of the year. So this is my presentation, and I was told to stop sharp here in time in order to take some of your questions. Thanks very much for your patience, and happy to take your questions. And otherwise, I welcome you to follow up our news flow. So this is not the last conference of this year.
There's one in Düsseldorf, and then JP Morgan is the first conference beginning of next year, where I'm happy to see all of you again, and then by March of next year, we will report about our annual data for 2025 and also give a guidance for the next year. Thank you very much. Any questions?
Just a boring bookkeeping question. Sorry about that. Last financial calls, you talked a lot about comparing apples and peers because of the, you know, the one times income, license income, which come in just in one quarter and not another quarter. Could you elaborate a little about that?
Yeah, I'm happy to do so. So we have our... Most of our business is recurring business. Consumables, selling, selling, selling, selling again, again. But sometimes we are also entering into a cooperation agreement with pharma companies because they are very keen on learning about our technique, and that is the reason why we are entering into license deals. They pay us money upfront, and we transfer them some techniques in order to produce, and that we did with a Chinese company. This we have done with an Australian company called Telix, and then there are some milestone payments related to that business. One of them was in Q4 last year, another one was Q1 this year, and we are expecting in this quarter and also in the beginning of next quarter, more milestones. So these are some hiccups, and they are, of course, more difficult to predict.
That's why if I want to really focus on the operative business, then I'm saying, "Well, let's see how much money we are selling, making with selling the generator or the isotopes or the radiopharmaceuticals as such, and not so much about the license income." But at the end of the day, money is money, and we take whatever we can. Any other questions? If this is not the case, then thank you very much for being here, and looking forward to seeing you again. Thank you.